1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,394 | 0,474 | 12.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | ABBISKO-B (02256): DISCLOSEABLE TRANSACTION - SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 27.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 20.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE CDE FOR ABBISKO THERAPEUTICS' ORAL PD-L1 INHIBITOR ABSK043 IN COMBINATION WITH KRAS ... | 1 | HKEx | ||
| 20.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 05.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 04.08. | ABBISKO-B (02256): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 04.08. | ABBISKO-B (02256): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
| 23.07. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS DOSES FIRST PATIENT IN PHASE 1 CLINICAL TRIAL FOR ABSK131, A NOVEL PRMT5*MTA INHIBITOR | 3 | HKEx | ||
| 16.07. | ABBISKO-B (02256): DATE OF BOARD MEETING | 2 | HKEx | ||
| 27.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 26.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS TO PRESENT UPDATED RESULTS FROM THE PHASE 2 STUDY OF IRPAGRATINIB IN COMBINATION WITH ... | 1 | HKEx | ||
| 23.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT ENROLLMENT OF OBSERVATIONAL STUDY FOR THE TREATMENT OF ACHONDROPLASIA | 1 | HKEx | ||
| 20.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 18.06. | ABBISKO-B (02256): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 18, 2025 | 1 | HKEx | ||
| 16.06. | Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC | 126 | PR Newswire | SHANGHAI, June 15, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational... ► Artikel lesen | |
| 16.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN REGISTRATIONAL STUDY OF IRPAGRATINIB FOR HCC | 2 | HKEx | ||
| 12.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING OF THE COMPANY BY THE FOUNDER, THE EXECUTIVE DIRECTOR, THE CHIEF EXECUTIVE OFFICER ... | 3 | HKEx | ||
| 12.06. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 12.06. | ABBISKO-B (02256): ANNOUNCEMENT MADE PURSUANT TO RULES 13.51B(2) AND 13.51(2) OF THE LISTING RULES | 1 | HKEx | ||
| 10.06. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES CHINA NMPA ACCEPTANCE OF NDA FOR PIMICOTINIB FOR THE TREATMENT OF TGCT | 1 | HKEx |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 18,940 | +1,83 % | Summit Therapeutics rises as co-CEOs buy nearly $12M worth of company stock | ||
| BIONTECH | 82,50 | +0,06 % | BioNTech erreicht Phase-3-Erfolg bei Brustkrebsstudie mit BNT323 | BioNTech hat gemeinsam mit DualityBio einen wichtigen Studienerfolg erzielt: In einer von DualityBio in China durchgeführten Phase-3-Studie erreichte der Antikörper-Wirkstoff-Kandidat Trastuzumab Pamirtecan... ► Artikel lesen | |
| ARCELLX | 76,19 | -1,92 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,110 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 38,885 | -0,29 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 44,710 | +8,94 % | Avidity Biosciences: BofA Securities erhöht Kursziel auf 65 US-Dollar | ||
| EVOTEC | 5,818 | -0,34 % | Evotec Aktie: Es sieht übel aus, aber... | Bei der Evotec Aktie sieht es charttechnisch nicht gut aus. Zwar zeigt sich aktuell auf Tradegate für die Biotech-Aktie ein positiver Tagestrend, doch das Gesamtbild im Kursverlauf bleibt negativ geprägt.... ► Artikel lesen | |
| TOURMALINE BIO | 47,600 | 0,00 % | Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen | DJ Novartis will Tourmaline Bio für 1,4 Milliarden Dollar übernehmen
Von Adam Whittaker
DOW JONES--Novartis will das US-Biopharmaunternehmen Tourmaline Bio für rund 1,4 Milliarden US-Dollar... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,750 | +2,37 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| MAZE THERAPEUTICS | 23,270 | -6,17 % | Maze Therapeutics, Inc.: Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria ... | Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,530 | -4,39 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 37,060 | -0,32 % | Hedge Fund and Insider Trading News: Louis Bacon, Bill Ackman, Warren Buffett, Dan Loeb, Silver Point Capital, Starboard Value, Elliott Management, Mineralys Therapeutics Inc (MLYS), DuPont de Nemours Inc (DD), and More | ||
| ENLIVEN THERAPEUTICS | 19,960 | +0,20 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of patients achieving MMR by 24 weeks... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 49,380 | -4,80 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| TREVI THERAPEUTICS | 8,250 | -15,38 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates | Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF
Closed $115 million underwritten... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,930 Euro und damit +5,46 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.